Solabegron - Velicept Therapeutics

Drug Profile

Solabegron - Velicept Therapeutics

Alternative Names: 427353; GW-427353; GW-427353B; Solabegron; Solabegron hydrochloride

Latest Information Update: 08 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer AltheRx; Velicept Therapeutics
  • Class Aniline compounds; Antihyperglycaemics; Benzoic acids; Obesity therapies; Small molecules
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Irritable bowel syndrome; Overactive bladder
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 09 Jul 2018 Phase-II clinical trials in Overactive bladder in USA (PO) (NCT03594058)
  • 19 Mar 2018 Velicept Therapeutics plans the phase IIb VEL2001 trial of once daily formulation of solabegron for Overactive bladder, in the second quarter of 2018
  • 19 Mar 2018 Velicept Therapeutics receives US patent covering for solabegron in Overactive bladder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top